Protease Inhibitors In Aids Therapy (Hardbound - 2001)

About the Book
Details the evolution of HIV protease inhibitors from molecular development through medical applications

Considering the latest class of revolutionary drugs fighting against HIV infection and AIDS, this comprehensive reference thoroughly examines the development and properties of HIV protease inhibitors from clinical and scientific perspectives, discussing how protease inhibitors changed the FDA approval process-enhancing the collaboration between regulatory authorities and drug developers.

Spotlights protease inhibitors as the cornerstone drugs of the first HAART regimens-key components of long-term viral suppression and immune restoration, and in secondary and tertiary regimens

Evaluating protease inhibitors as therapeutic options and research tools, Protease Inhibitors in AIDS Therapy

reviews the impact of advances in recombinant DNA technology for understanding and treating HIV and AIDS

highlights a variety of strategies and techniques for drug discovery and development illustrated by success stories of pharmaceutical companies and biotechnology start-up firms

summarizes the pharmacokinetics, metabolism, and drug interactions of protease inhibitors

details preliminary clinical studies on oral bioavailability, pharmacokinetic profiling, efficacy, resistance, and tolerability

describes available efficacy data for marketed inhibitors and those in clinical development

reports on efforts to manage antiviral resistance in the clinic and improve patient adherence to complex drug therapy

and more
Containing more than 600 helpful literature references, drawings, photographs, and tables, Protease Inhibitors in AIDS Therapy serves for an essential reference for infectious disease specialists, epidemiologists, virologists, immunologists, pharmacologists, medicinal chemists and biochemists, microbiologists, hematologists, hepatologists, and medical students in these disciplines.